Literature DB >> 31818533

Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.

Zhizeng Gao1, Kyle Robinson1, Danuta M Skowronski2, Gaston De Serres3, Stephen G Withers4.   

Abstract

The protective immunological effects of the influenza neuraminidase (NA) surface protein are of renewed interest but NA content in vaccines remains unstandardized and methods to easily and reliably quantify NA content are unsatisfactory. We describe the use of a recently developed fluorometric titration reagent, TR1, to efficiently quantify the total enzymatically active NA content of six commercially-available influenza vaccines, including split/subunit, inactivated/live and standard /high dose products distributed from 2015/16 to 2017/18 in North America. Considerable differences in active NA content were measured between influenza vaccine products for the same season, with relative content differences between brands generally maintained across seasons. These results highlight the simplicity of use of this reagent, and its unique ability to quantitate enzymatically active NA without the need for specific activities of individual enzymes. The reagent could also prove valuable in assessing the importance of using fully active enzyme to generate protective immune responses.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Active-site titration; HA and NA levels in vaccines; Neuraminidase content

Mesh:

Substances:

Year:  2019        PMID: 31818533     DOI: 10.1016/j.vaccine.2019.11.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.

Authors:  Jin Gao; Laura Klenow; Lisa Parsons; Tahir Malik; Je-Nie Phue; Zhizeng Gao; Stephen G Withers; John Cipollo; Robert Daniels; Hongquan Wan
Journal:  J Virol       Date:  2021-10-06       Impact factor: 5.103

Review 2.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

3.  Development of an active site titration reagent for α-amylases.

Authors:  Ryan P Sweeney; Phillip M Danby; Andreas Geissner; Ryan Karimi; Jesper Brask; Stephen G Withers
Journal:  Chem Sci       Date:  2020-11-03       Impact factor: 9.825

Review 4.  Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.

Authors:  Luca T Giurgea; David M Morens; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Vaccines (Basel)       Date:  2020-07-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.